The latest data from GW Pharma is about as conclusively positive as you can usually hope to get with a new drug, smashing performance against placebo on both primary and secondary endpoints.
The stage looks set for the first approval of a cannabis-derived product, barring any unexpected surprises. Uncertainty over how a drug made from a plant that is designated as a Schedule I by the DEA, which means that it is regarded as having no potential medical value, has never really left the background of the GW’s work.
